Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir in Uncomplicated Influenza
NCT01068912Phase 2Completed
- Sponsor
- MDVI, LLC
- Start
- Feb 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of favipiravir in influenza (3 arms), sponsored by MDVI, LLC. Primary endpoint: Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza at 22 weeks. Started Feb 2010; status: completed.
02
Drugs
favipiravir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01068912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068912.